- $3.13bn
- $4.09bn
- CNY4.55bn
- 58
- 48
- 96
- 74
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 98.5 | 853 | 1,831 | 2,852 | 4,552 |
Cost of Revenue | |||||
Gross Profit | -36.8 | 243 | 733 | 1,200 | 1,893 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 220 | 910 | 1,803 | 2,177 | 3,363 |
Operating Profit | -121 | -57.5 | 28.2 | 675 | 1,188 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -141 | -171 | -216 | 471 | 946 |
Provision for Income Taxes | |||||
Net Income After Taxes | -138 | -170 | -283 | 316 | 652 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -138 | -174 | -283 | 316 | 652 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -138 | -174 | -283 | 316 | 652 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.174 | -0.249 | -0.462 | 0.434 | 0.968 |